SUBSCRIBE
SUBSCRIBE
News   Business

XenoPort, Inc. Amends Agreement With GlaxoSmithKline On RLS Drug, Horizant; Milestone Payments Changed; Xenoport Reacquires Rights Outside of the U.S.

November 8, 2010 | 
1 min read
Nov 8 (Reuters) - Biopharmaceutical company XenoPort Inc (XNPT.O) amended an agreement with GlaxoSmithKline (GSK.L) for the development of its drug to treat restless legs syndrome (RLS).
Alliances
GSK
MORE ON THIS TOPIC
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Funding
Recordati fields $12.4B go-private offer
May 22, 2026
 · 
2 min read
 · 
Tristan Manalac
High Quality background with Two Flags of South Korea and USA
Manufacturing
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
May 22, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
AbbVie, Novartis slash US headcount
May 22, 2026
 · 
55 min read
 · 
BioSpace Editorial Staff
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
 · 
3 min read
 · 
Tristan Manalac